Search

Displaying results 3001 - 3010 of 10000 in total
  1. Drug

    Ciclesonide

    go.drugbank.com/drugs/DB01410
    ApprovedInvestigational

    Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.

  2. Drug

    Eluxadoline

    go.drugbank.com/drugs/DB09272
    ApprovedInvestigational

    of abdominal pain and reductions in the Bristol Stool Scale. … The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system.

  3. Drug

    Butorphanol

    go.drugbank.com/drugs/DB00611
    ApprovedIllicitVet approved

    It is used in the management of severe pain.

    Synonyms: (−)-N-cyclobutylmethyl-3,14-dihydroxymorphinan
  4. Drug

    Honey

    go.drugbank.com/drugs/DB14242
    ApprovedInvestigational

    Honey is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

  5. Drug

    Dinoprost tromethamine

    go.drugbank.com/drugs/DB01160
    ApprovedVet approvedWithdrawn

    The tromethamine (THAM) salt of the naturally occurring prostaglandin F2 alpha, dinoprost tromethamine occurs as a white to off-white, very hygroscopic, crystalline powder. Dinoprost tromethamine may also be known as dinoprost trometamol...

  6. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    [L64069] The FDA approved oveporexton on August 5, 2026 for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults. … Oveporexton is an orally administered orexin receptor 2 (OX2R) agonist used to treat narcolepsy type 1 (NT1).

  7. Drug

    Bebtelovimab

    go.drugbank.com/drugs/DB16755
    ApprovedWithdrawn

    in the US. … [L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients.

  8. Drug

    Oglufanide

    go.drugbank.com/drugs/DB05779
    Investigational

    Oglufanide was originally developed to treat severe infectious disease in Russia (where it is a registered pharmaceutical), and was extensively studied in cancer clinical trials in the United States before … being acquired by Implicit Bioscience in 2005.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Lumiliximab

    go.drugbank.com/drugs/DB06162
    Investigational

    Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. Results published from the CLL clinical trial failed to meet primary endpoints. … Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.

    Synonyms: IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER, IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULPHIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER
  10. Drug

    Burosumab

    go.drugbank.com/drugs/DB14012
    ApprovedInvestigational

    Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic … Food and Drug Administration approved Crysvita (burosumab) in April 2018.